What is claimed is:

1. Use of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a muscarinic receptor antagonist in the manufacture of a medicament for the treatment of a condition associated with pharyngeal airway collapse in a subject; wherein an effective amount of the NRI and the muscarinic receptor antagonist are to be administered to the subject.

2. The use of claim 1, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

3. The use of claim 2, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

4. The use of claim 1, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Phenmetrazine, Protryptyline, Radafaxine, Tapentadol, Teniloxazine, and Venlafaxine.

5. The use of claim 1, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

6. The use of claim 5, wherein the NRI is Atomoxetine.

7. The use of claim 6, wherein the Atomoxetine is to be administered to the subject at a dose of 20-100 mg.

8. The use of claim 6, wherein the Atomoxetine is to be administered to the subject at a dose of 25-75 mg.

9. The use of claim 1, wherein the muscarinic receptor antagonist is selected from the group consisting of Atropine, Propantheline, Bethanechol, Solifenacin, Darifenacin, Tolterodine, Fesoterodine, Trospium, and Oxybutynin.

10. The use of claim 1, wherein the muscarinic receptor antagonist is selected from the group consisting of Anisotropine, Benztropine, Biperiden, Clidinium, Cycrimine, Dicyclomine, Diphemanil, Diphenidol, Ethopropazine, Glycopyrrolate, Hexocyclium, Isopropamide, Mepenzolate, Methixene, Methscopolamine, Oxyphencyclimine, Oxyphenonium, Procyclidine, Scopolamine, Tridihexethyl and Trihexyphenidyl.

11. The use of claim 1, wherein the muscarinic receptor antagonist is in an immediate release formulation.

12. The use of claim 1, wherein the muscarinic receptor antagonist is in an extended release formulation.

13. The use of any one of claims 1-12, wherein the muscarinic receptor antagonist is Oxybutynin.

14. The use of claim 13, wherein the Oxybutynin is to be administered to the subject at a dose of 2-15 mg.

15. The use of claim 14, wherein the Oxybutynin is in an immediate release formulation with a dose of 2.5-10 mg.

16. The use of claim 14, wherein the Oxybutynin is in an extended release formulation with a dose of 5-15 mg.

17. The use of any one of claims 1-16, wherein the condition is Obstructive Sleep Apnea or Simple Snoring.

18. The use of claim 17, wherein the condition is Obstructive Sleep Apnea.

19. The use of claim 1, wherein the NRI and the muscarinic receptor antagonist are to be administered to the subject in a single composition.

20. The use of claim 19, wherein the single composition is an oral administration form.

21. The use of claim 20, wherein the oral administration form is a syrup, pill, tablet, troche, or capsule.

22. Use of (i) atomoxetine and (ii) oxybutynin in the manufacture of a medicament for treating sleep apnea in a subject, wherein an effective amount of the atomoxetine and oxybutynin are to be administered to the subject.

23. Use of (i) atomoxetine and (ii) oxybutynin in the manufacture of a medicament for treating snoring in a subject, wherein an effective amount of the atomoxetine and oxybutynin are to be administered to the subject.